Liquidia Technologies, Inc. (LQDA): Price and Financial Metrics
LQDA Price/Volume Stats
| Current price | $6.29 | 52-week high | $9.95 |
| Prev. close | $6.33 | 52-week low | $4.35 |
| Day low | $6.23 | Volume | 35,793 |
| Day high | $6.32 | Avg. volume | 516,563 |
| 50-day MA | $6.97 | Dividend yield | N/A |
| 200-day MA | $7.20 | Market Cap | 407.22M |
LQDA Stock Price Chart Interactive Chart >
LQDA POWR Grades
- Value is the dimension where LQDA ranks best; there it ranks ahead of 60.32% of US stocks.
- LQDA's strongest trending metric is Growth; it's been moving down over the last 177 days.
- LQDA ranks lowest in Growth; there it ranks in the 10th percentile.
LQDA Stock Summary
- With a price/sales ratio of 23.22, LIQUIDIA CORP has a higher such ratio than 94.98% of stocks in our set.
- With a year-over-year growth in debt of 51.81%, LIQUIDIA CORP's debt growth rate surpasses 84.81% of about US stocks.
- Revenue growth over the past 12 months for LIQUIDIA CORP comes in at 28.98%, a number that bests 80.67% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to LIQUIDIA CORP, a group of peers worth examining would be AKTS, PSNL, VECO, CYN, and APLS.
- Visit LQDA's SEC page to see the company's official filings. To visit the company's web site, go to www.liquidia.com.
LQDA Valuation Summary
- In comparison to the median Healthcare stock, LQDA's price/sales ratio is 1121.05% higher, now standing at 23.2.
- LQDA's price/sales ratio has moved up 0.1 over the prior 63 months.
Below are key valuation metrics over time for LQDA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| LQDA | 2023-09-22 | 23.2 | 6.8 | -8.1 | -7.7 |
| LQDA | 2023-09-21 | 23.3 | 6.8 | -8.2 | -7.8 |
| LQDA | 2023-09-20 | 22.8 | 6.7 | -8.0 | -7.6 |
| LQDA | 2023-09-19 | 23.6 | 6.9 | -8.2 | -7.8 |
| LQDA | 2023-09-18 | 23.5 | 6.9 | -8.2 | -7.8 |
| LQDA | 2023-09-15 | 23.5 | 6.9 | -8.2 | -7.8 |
LQDA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- LQDA has a Quality Grade of D, ranking ahead of 6.72% of graded US stocks.
- LQDA's asset turnover comes in at 0.106 -- ranking 153rd of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows LQDA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.106 | 0.756 | -1.103 |
| 2021-06-30 | 0.075 | 0.771 | -1.558 |
| 2021-03-31 | 0.049 | 0.756 | -2.131 |
| 2020-12-31 | 0.011 | 0.679 | -2.776 |
| 2020-09-30 | 0.000 | NA | -3.022 |
| 2020-06-30 | 0.000 | NA | -2.692 |
LQDA Price Target
For more insight on analysts targets of LQDA, see our LQDA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $4.25 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Liquidia Technologies, Inc. (LQDA) Company Bio
Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase Ib clinical trials for the treatment of local post-operative pain. The company was founded in 2004 and is based in Morrisville, North Carolina.
Latest LQDA News From Around the Web
Below are the latest news stories about LIQUIDIA CORP that investors may wish to consider to help them evaluate LQDA as an investment opportunity.
FDA Accepts Submission to Add PH-ILD to YUTREPIA™ LabelSets PDUFA goal date of January 24, 2024If approved, YUTREPIA would be indicated for treatment of both PAH and PH-ILD MORRISVILLE, N.C., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the Company’s amendment to the tentatively approved new drug application (NDA) for YUTREPIA™ (treprostinil) inhalation powder in which the Company is seeking to add the treatment of pulmonary h |
United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent OfficeAsserts ‘793 patent in new litigation filed under Hatch-Waxman Act in response to Liquidia’s amendment to its NDA to add PH-ILD to YUTREPIA™ labelLitigation is tied to same ‘793 patent previously ruled invalid by Patent Trial and Appeal Board (PTAB) MORRISVILLE, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company), announced today that United Therapeutics Corporation (UTHR) filed a patent infringement action under the Hatch-Waxman Act in the U.S. |
Q2 2023 Liquidia Corp Earnings CallQ2 2023 Liquidia Corp Earnings Call |
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Tops Revenue EstimatesLiquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -111.76% and 0.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateMORRISVILLE, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the second quarter ended June 30, 2023. The Company will host a webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate update. Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said: “This quarter saw Liquidia significantly advance our mission to become the leading inhaled treprostinil provider for pulmonary hypertens |
LQDA Price Returns
| 1-mo | N/A |
| 3-mo | -17.56% |
| 6-mo | N/A |
| 1-year | 9.97% |
| 3-year | 26.81% |
| 5-year | -79.85% |
| YTD | -1.26% |
| 2022 | 30.80% |
| 2021 | 65.08% |
| 2020 | -30.99% |
| 2019 | -80.26% |
| 2018 | N/A |
Continue Researching LQDA
Want to see what other sources are saying about Liquidia Technologies Inc's financials and stock price? Try the links below:Liquidia Technologies Inc (LQDA) Stock Price | Nasdaq
Liquidia Technologies Inc (LQDA) Stock Quote, History and News - Yahoo Finance
Liquidia Technologies Inc (LQDA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...